Journal Article Summary
The article investigates the effectiveness of intravenous (IV) cetirizine compared to IV diphenhydramine in preventing hypersensitivity infusion reactions in patients receiving certain cancer treatments. This topic is significant because hypersensitivity reactions can occur during infusions of biologic agents and chemotherapy, potentially leading to severe complications. The study aims to explore a newer antihistamine option, cetirizine, which has been associated with fewer side effects, particularly sedation, compared to the traditional diphenhydramine.
In this exploratory phase 2 study, 34 patients were randomly assigned to receive either IV cetirizine (10 mg) or IV diphenhydramine (50 mg) before their infusion of an anti-CD20 agent or paclitaxel. The results showed that both medications were similarly effective in preventing infusion reactions, with incidences of 11.8% for cetirizine and 17.6% for diphenhydramine. However, cetirizine was linked to less sedation, shorter time spent in the infusion center, and fewer treatment-related adverse events, making it a potentially better option for patients.
Despite the promising findings, the study has limitations, including a small sample size, which may affect the generalizability of the results. Patients should discuss these findings with their healthcare providers, especially if they are elderly or have concerns about sedation and side effects associated with diphenhydramine. The study highlights the need for further research to confirm the benefits of cetirizine and its role in improving patient safety and satisfaction during cancer treatment infusions.
Medication Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Holmes Jarrod P., Peguero Julio A., Garland R. Campbell, North Janine, Young Stacia, Brent Lonnie D., Joseph-Ridge Nancy. Intravenous Cetirizine vs Intravenous Diphenhydramine for the Prevention of Hypersensitivity Infusion Reactions: Results of an Exploratory Phase 2 Study. Journal of Infusion Nursing 2021. DOI: 10.1097/NAN.0000000000000444. PMID: 34555839. PMCID: PMC8565502.
Featured Pill Pals Product
Cetirizine 10 mg Tablets - 500 count - Generic For Zyrtec --- DR REDDY
Cetirizine 10 mg Tablets - 500 count - Generic For Zyrtec --- DR REDDY is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. No prescription required for eligible over-the-counter purchases.
